KLA stock jumps toward a fresh high as chip-equipment rally kicks off 2026
5 January 2026
1 min read

KLA stock jumps toward a fresh high as chip-equipment rally kicks off 2026

NEW YORK, January 4, 2026, 20:49 ET — Market closed

  • KLA shares ended Friday up 4.9% at $1,274.47, near a 52-week high. 1
  • Semiconductor equipment names rose with a broader chip rebound on the first U.S. session of 2026. 2
  • Traders head into Monday focused on Friday’s breakout levels and Friday’s U.S. jobs report (Jan. 9). 3

KLA Corp (KLAC) shares surged nearly 5% on Friday, ending the first trading session of 2026 within about 1% of their 52-week high after chip-linked stocks rebounded. 1

The move matters now because KLA sells process-control tools — equipment that inspects wafers and identifies defects to lift “yield,” the share of usable chips coming off a production line. Those orders are a read-through on semiconductor capital spending, a key driver for the equipment group. 4

Next catalysts are split between the macro calendar and the company’s earnings setup. The U.S. government is due to release the December employment report on Friday, Jan. 9 at 8:30 a.m. ET, while KLA’s own investor relations calendar currently lists no upcoming events. 3

KLAC closed Friday at $1,274.47, up 4.9% from its prior close, according to market data. The stock’s 52-week high stands at $1,286.81. 1

KLA’s gain came alongside a sharp move across semiconductor equipment peers. ASML’s U.S.-listed shares rose 8.7%, Lam Research jumped 8.1% and Applied Materials added 4.6%, while the iShares Semiconductor ETF climbed 4.2%.

The broader tape was less decisive. The Dow and S&P 500 finished higher on Friday as chip stocks outperformed, while the Nasdaq ended roughly flat, Reuters reported. 2

KLA has framed the current cycle around rising chip complexity tied to AI infrastructure. “KLA produced a strong all-around September quarter performance above the guidance midpoints,” CEO Rick Wallace said in the company’s most recent quarterly results statement. 4

In that report, KLA guided fiscal second-quarter revenue to $3.225 billion plus or minus $150 million, with non-GAAP earnings per share of $8.70 plus or minus $0.78. Investors will gauge the next print against those ranges, with close attention on margins and demand from memory and advanced packaging customers. 4

But the stock’s proximity to its high leaves less room for disappointment if chipmaker spending cools or if trade rules tighten. KLA has warned that evolving U.S. export controls can affect its ability to sell and service certain customers in China, a swing market for the equipment cycle. 4

For Monday’s session, traders will watch whether KLAC can break and hold above $1,286.81, with the next hard calendar catalyst on Friday, Jan. 9, when the U.S. jobs report hits at 8:30 a.m. ET. 1

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Uber stock: UK ‘taxi tax’ contract rewrite puts VAT risk in focus ahead of Monday trade
Previous Story

Uber stock: UK ‘taxi tax’ contract rewrite puts VAT risk in focus ahead of Monday trade

Chevron stock in spotlight after U.S. Venezuela embargo halts cargoes ahead of Monday
Next Story

Chevron stock in spotlight after U.S. Venezuela embargo halts cargoes ahead of Monday

Go toTop